Xing Lv, Xun Cao, Wei-Xiong Xia, Kui-Yuan Liu, Meng-Yun Qiang, Ling Guo, Chao-Nan Qian, Ka-Jia Cao, Hao-Yuan Mo, Xian-Ming Li, Zi-Huang Li, Fei Han, Yu-Xiang He, Yu-Meng Liu, Shao-Xiong Wu, Yong-Rui Bai, Liang-Ru Ke, Wen-Ze Qiu, Hu Liang, Guo-Ying Liu, Jing-Jing Miao, Wang-Zhong Li, Shu-Hui Lv, Xi Chen, Chong Zhao, Yan-Qun Xiang, Xiang Guo
BACKGROUND: Cisplatin-based induction chemotherapy plus concurrent chemoradiotherapy in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma has been recommended in the National Comprehensive Cancer Network Guidelines. However, cisplatin is associated with poor patient compliance and has notable side-effects. Lobaplatin, a third-generation platinum drug, has shown promising antitumour activity against several malignancies with less toxicity. In this study, we aimed to evaluate the efficacy of lobaplatin-based induction chemotherapy plus concurrent chemoradiotherapy over a cisplatin-based regimen in patients with locoregional, advanced nasopharyngeal carcinoma...
April 12, 2021: Lancet Oncology